Ibuprofen delivered by poly(lactic-co-glycolic acid) (PLGA) nanoparticles to human gastric cancer cells exerts antiproliferative activity at very low concentrations

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5683-5691

  Bonelli, Patrizia ^a   Tuccillo, Franca M ^a   Federico, Antonella ^b   Napolitano, Maria ^a   Borrelli, Antonella ^a   Melisi, Daniela ^c   Rimoli, Maria G ^c   Palaia, Raffaele ^a   Arra, Claudio ^a   Carinci, Francesco ^d  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Microtech Laboratory   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

Author keywords

MKN 45 cells; Nonsteroidal anti inflammatory drug (NSAID); Proliferation; Uptake

Indexed keywords

ANGIOPOIETIN; IBUPROFEN; MESSENGER RNA; NANOPARTICLE; POLYGLACTIN;

ANGIOPOIETIN LIKE PROTEIN 4 GENE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HUMAN; HUMAN CELL; MASS FRAGMENTOGRAPHY; NANOPHARMACEUTICS; STOMACH CANCER; TIMED DRUG RELEASE; TUMOR GENE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IBUPROFEN; LACTIC ACID; NANOCAPSULES; PARTICLE SIZE; POLYGLYCOLIC ACID; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84870359867     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S34723     Document Type: Article

References (40)

1. Kokoska ER, Smith GS, Wolff AB, Deshpande Y, Miller TA. Nonsteroidal anti-inflammatory drugs attenuate epidermal growth factor-induced proliferation independent of prostaglandin synthesis inhibition. J Surg Res. 1999;84(2):186-192.
2. Thun MJ. NSAID use and decreased risk of gastrointestinal cancers. Gasteroenterol Clin North Am. 1996;25(2):333-348.
3. Giardiello FM. NSAID-induced polyp regression in familial adenomatous polyposis patients. Gasteroenterol Clin North Am. 1996;25(2):349-362.
4. Barnes CJ, Cameron IL, Hardman WE, Lee M. Non-steroidal anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis. Br J Cancer. 1998;77(4):573-580.
5. Fratelli M, Minto M, Crespi A, etal. Inhibition of nuclear factor-kappaB by a nitro-derivative of flurbiprofen: a possible mechanism for anti-inflammatory and antiproliferative effect. Antioxid Redox Signal. 2003;5(2):229-235.
6. Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res. 2003;37:1-24.
7. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ. 2000;320(7250):1642-1646.
8. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2003;95(23):1784-1791.
9. Bonelli P, Tuccillo FM, Calemma R, etal. Changes in the gene expression profile of gastric cancer cells in response to ibuprofen: a gene pathway analysis. The Pharmacogenomics J. 2011;11(6):412-428.
10. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54(5):631-651.
11. Wang K, Ruan J, Qian Q, etal. BRCAA1monoclonal antibody conjugated fluorescent magnetic nanoparticles for in vivo targeted magnetofluorescent imaging of gastric cancer. J Nanobiotechnology. 2011;9:23.
12. Jain KK. Nanotechnology-based drug delivery for cancer. Technol Cancer Res Treat. 2005;4(4):407-416.
13. Cengelli F, Grzyb JA, Montoro A, Hofmann H, Hanessian S, Juillerat-Jeanneret L. Surface-functionalized ultrasmall superparamagnetic nanoparticles as magnetic delivery vectors for camptothecin. Chem Med Chem. 2009;4(6):988-997.
14. Kuo F, Subramanian B, Kotyla T, Wilson TA, Yoganathan S, Nicolosi RJ. Nanoemulsions of an anti-oxidant synergy formulation containing gamma tocopherol have enhanced bioavailability and anti-inflammatory properties. Intl J Pharm. 2008;363(1):206-213.
15. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres: Adv Drug Deliv Rev. 1997;28(1):5-24.
16. Fournier E, Passirani C, Montero-Menei CN, Benoit JP. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials. 2003;24(19):3311-3331.
17. Middleton JC, Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. Biomaterials. 2000;21(23):2335-2346.
18. Wu L, Ding J. In vitro degradation of three-dimensional porous poly(D, L-lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials. 2004;25(27):5821-5830.
19. Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm. 2007;336(2):367-375.
20. Teixeira M, Alonso MJ, Pinto MM, Barbosa CM. Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone. Eur J Pharm Biopharm. 2005;59(3):491-500.
21. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3-19.
22. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000;21(23):2475-2490.
23. Vert M. The complexity of PLGA-based drug delivery systems. In: Proceedings of the International Conference on Advances in Controlled Delivery. Baltimore, MD; 1996:32-36.
24. John-Aryankalayil M, Palayoor ST, Cerna D, Falduto MT, Magnuson SR, Coleman CN. NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells. Mol Cancer Ther. 2009;8(1):261-273.
25. Yoon JC, Chickering TW, Rosen ED, etal. Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol Cell Biol. 2000;20(14):5343-5349.
26. Li KQ, Li WL, Peng SY, Shi XY, Tang HL, Liu YB. Anti-tumor effect of recombinant retroviral vector-mediated human ANGPTL4gene transfection. Chin Med J (Eng). 2004;117(9):1364-1369.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods. 2001;25(4):402-408.
28. Nkansah MK, Thakral D, Shapiro EM. Magnetic poly(lactide-co-glycolide) and cellulose particles for MRI-based cell tracking. Mag Reson Med. 2011;65(6):1776-1785.
29. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Rel. 2007;120(1-2):18-26.
30. Cartiera MS, Johnson KM, Rajendran V, Caplan MJ, Saltzman WM. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials. 2009;30(14):2790-2798.
31. Yang J, Lee CH, Park J, etal. Antibody conjugated magnetic PLGA nanoparticles for diagnosis and treatment of breast cancer. J Mater Chem. 2007;17:2695-2699.
32. Park J, Fong PM, Lu J, etal. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine. 2009;5(4):410-418.
33. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002;16(10):1217-1226.
34. Fernández-Carballido A, Herrero-Vanrell R, Molina-Martínez IT, Pastoriza P. Sterilized ibuprofen-loaded poly(D, L-lactide-co-glycolide) microspheres for intra-articular administration: effect of gamma-irradiation and storage. J Microencapsul. 2004;21(6):653-665.
35. Fernández-Carballido A, Herrero-Vanrell R, Molina-Martínez IT, Pastoriza P. Biodegradable ibuprofen-loaded PLGA microspheres for intraarticular administration. Effect of Labrafil addition on release in vitro. Int J Pharm. 2004;279(1-2):33-41.
36. Klose D, Siepmann F, Elkharraz K, Siepmann J. PLGA-based drug delivery systems: importance of the type of drug and device geometry. Int J Pharm. 2008;354(1-2):95-103.
37. Pang J, Luan Y, Li F, Cai X, Du J, Li Z. Ibuprofen-loaded poly(lactic-co-glycolic acid) films for controlled drug release. Int J Nanomedicine. 2011;6:659-665.
38. Panyam J, Dali MM, Sahoo SK, etal. Polymer degradation and in vitro release of a model protein from poly(D, L-lactide-co-glycolide) nano-and microparticles. J Control Release. 2003;92(1-2):173-187.
39. Barratt GM. Therapeutic applications of colloidal drug carriers. Pharm Sci Technolo Today. 2000;3(5):163-171.
40. Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004;21(5):387-422.